{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T04:11:44Z","timestamp":1792987904275,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bone.2020.115501","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T00:52:46Z","timestamp":1593219166000},"page":"115501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["On the pharmacological evaluation of bisphosphonates in humans"],"prefix":"10.1016","volume":"139","author":[{"given":"Serge","family":"Cremers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank (Hal)","family":"Ebetino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Phipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115501_bb0005","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bone.2020.115501_bb0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/223211a0","article-title":"Prevention by a diphosphonate of immobilization \u201costeoporosis\u201d in rats","volume":"223","author":"Fleisch","year":"1969","journal-title":"Nature"},{"key":"10.1016\/j.bone.2020.115501_bb0015","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1126\/science.165.3899.1264","article-title":"Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo","volume":"165","author":"Francis","year":"1969","journal-title":"Science"},{"key":"10.1016\/j.bone.2020.115501_bb0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0140-6736(69)92293-4","article-title":"Diphosphonates in the treatment of myositis ossificans","volume":"2","author":"Bassett","year":"1969","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2020.115501_bb0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1359\/jbmr.2003.18.5.868","article-title":"Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget\u2019s disease of bone","volume":"18","author":"Cremers","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0030","first-page":"270","article-title":"The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease","volume":"19","author":"Fogelman","year":"1978","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.bone.2020.115501_bb0035","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/00365518409083629","article-title":"Measurements of whole body retention of diphosphonate and other indices of bone metabolism in 125 normals: dependency on age, sex and glomerular filtration","volume":"44","author":"Hyldstrup","year":"1984","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.bone.2020.115501_bb0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/00365518409161390","article-title":"Urinary 99m-Tc-diphosphonate excretion as a simple method to quantify bone metabolism","volume":"44","author":"Hyldstrup","year":"1984","journal-title":"Scand. J. Clin. Lab. Invest."},{"key":"10.1016\/j.bone.2020.115501_bb0045","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1177\/0091270002239824","article-title":"The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function","volume":"43","author":"Skerjanec","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0055","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1359\/JBMR.050522","article-title":"Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases","volume":"20","author":"Cremers","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2020.115501_bb0060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","article-title":"Ibandronate: a clinical pharmacological and pharmacokinetic update","volume":"44","author":"Barrett","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0065","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1023\/A:1011024200280","article-title":"Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration","volume":"18","author":"Mitchell","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0070","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","article-title":"Studies of the oral bioavailability of alendronate","volume":"58","author":"Gertz","year":"1995","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bone.2020.115501_bb0075","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00198-005-1911-7","article-title":"Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn\u2019s disease","volume":"16","author":"Cremers","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115501_bb0080","author":"FDA"},{"key":"10.1016\/j.bone.2020.115501_bb0085","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejps.2015.11.011","article-title":"Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability","volume":"82","author":"Kim","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bone.2020.115501_bb0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00198-011-1791-y","article-title":"Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet","volume":"23","author":"McClung","year":"2012","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115501_bb0095","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/j.1552-4604.1997.tb04304.x","article-title":"Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function","volume":"37","author":"Berenson","year":"1997","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/ki.1975.70","article-title":"Renal secretion of diphosphonates in rats","volume":"8","author":"Troehler","year":"1975","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2020.115501_bb0105","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S0090-9556(25)08729-X","article-title":"Renal handling of alendronate in rats. An uncharacterized renal transport system","volume":"20","author":"Lin","year":"1992","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bone.2020.115501_bb0110","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jnci\/84.10.788","article-title":"Pharmacokinetics of pamidronate in patients with bone metastases","volume":"84","author":"Leyvraz","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bone.2020.115501_bb0115","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0120","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2020.115501_bb0130","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2020.115501_bb0135","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1210\/jc.2011-0412","article-title":"Effect of stopping risedronate after long-term treatment on bone turnover","volume":"96","author":"Eastell","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115501_bb0140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00198-015-3145-7","article-title":"Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study","volume":"27","author":"Naylor","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115501_bb0145","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00198-018-4460-6","article-title":"Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density","volume":"29","author":"Naylor","year":"2018","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115501_bb0150","first-page":"S81","article-title":"Head-to-head comparison of risedronate and alendronate pharmacokinetics at clinical doses","volume":"34","author":"Phipps","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115501_bb0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/jbmr.5650070507","article-title":"Retention of etidronate in human, dog, and rat","volume":"7","author":"Kasting","year":"1992","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0160","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.bone.2011.06.027","article-title":"Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover","volume":"49","author":"Peris","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115501_bb0165","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/bcp.13881","article-title":"Pharmacometrics and systems pharmacology for metabolic bone diseases","volume":"85","author":"Riggs","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0170","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/1097-0142(20010101)91:1<144::AID-CNCR19>3.0.CO;2-Q","article-title":"A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2020.115501_bb0175","first-page":"478","article-title":"A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases","volume":"7","author":"Berenson","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bone.2020.115501_bb0180","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0185","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","article-title":"A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis","volume":"57","author":"Cremers","year":"2002","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0190","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.oooo.2012.08.455","article-title":"Population pharmacokinetic and pharmacodynamic modeling for assessing risk of bisphosphonate-related osteonecrosis of the jaw","volume":"115","author":"Sedghizadeh","year":"2013","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.bone.2020.115501_bb0195","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.oooo.2013.09.076","article-title":"Bisphosphonate-related osteonecrosis of the jaws is caused by dental procedures that violate oral epithelium; this is no longer a mysterious disease","volume":"117","author":"Jones","year":"2014","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"key":"10.1016\/j.bone.2020.115501_bb0200","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2125.2004.02224.x","article-title":"A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis","volume":"58","author":"Pillai","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2020.115501_bb0205","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1196\/annals.1346.058","article-title":"Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans","volume":"1068","author":"Zaidi","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bone.2020.115501_bb0210","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bone.2009.08.053","article-title":"A physiologically based mathematical model of integrated calcium homeostasis and bone remodeling","volume":"46","author":"Peterson","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115501_bb0215","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1359\/jbmr.091009","article-title":"Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo","volume":"25","author":"Roelofs","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0220","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.2174\/138161210793563635","article-title":"Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages","volume":"16","author":"Roelofs","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bone.2020.115501_bb0225","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/jbmr.1543","article-title":"Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vivo","volume":"27","author":"Roelofs","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115501_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10030154","article-title":"Synthesis of a bone-targeted bortezomib with in vivo anti-myeloma effects in mice","volume":"10","author":"Wang","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bone.2020.115501_bb0235","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1021\/acs.jmedchem.6b01615","article-title":"Design, synthesis, and antimicrobial evaluation of a novel bone-targeting bisphosphonate-ciprofloxacin conjugate for the treatment of osteomyelitis biofilms","volume":"60","author":"Sedghizadeh","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bone.2020.115501_bb0240","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/jbmr.3860","article-title":"Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women","volume":"35","author":"Reid","year":"2020","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220302817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:49:01Z","timestamp":1757612941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220302817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":48,"alternative-id":["S8756328220302817"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115501","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On the pharmacological evaluation of bisphosphonates in humans","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115501","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115501"}}